The Cancer Letter

Inside information on cancer research and drug development

In Brief

Kids V Cancer named one of top 10 most innovative companies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

KIDS V CANCER was named as one of Fast Company’s Top 10 Most Innovative Companies of 2016 in Not-For-Profit, placing fourth. Fast Company praised Kids v Cancer for accelerating the discovery of pediatric cancer treatments.

Other organizations in this category include Black Lives Matter, 92nd St Y, Humans Of New York and UNICEF. Last year, Kids v Cancer received the 2015 Peter F. Drucker Award for Nonprofit Innovation.

Through the Creating Hope Act, Kids v Cancer has mobilized almost $1 billion for research and development of drugs. With the valuation of a Creating Hope Act pediatric priority review voucher reaching $350 million, biotech and pharmaceutical companies are now focusing on business plans built around pediatric rare disease drug development.

Table of Contents

YOU MAY BE INTERESTED IN

Black History MonthConversation with The Cancer Letter

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

By Jacquelyn Cobb
Guest Editorial

Biomarker-driven innovation: What the FDA’s evolving strategy means for oncology

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

By Harpreet Singh
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account